Gynecologic Cancer News

A new guideline issued by the American Society for Radiation Oncology addresses the use of radiation therapy for the treatment of nonmetastatic cervical cancer.

Health care providers should begin offering routine HPV vaccination to children as young as age 9 years in order to increase rates of on-time administration, according to an updated American Cancer Society guideline.

Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Though the combination of cediranib and olaparib did not beat out platinum-based chemotherapy, it was more effective in patients with germline BRCA mutations, according to Ursula A. Matulonis, MD, of Dana Farber Cancer Institute.

Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

The addition of berzosertib to gemcitabine extended PFS for women with platinum-resistant, high-grade serous ovarian cancer, according to results of a randomized phase 2 study published in The Lancet Oncology.

In the KEYNOTE-100 study, presented during the ASCO2020 Virtual Scientific Program, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, showed pembrolizumab had a modest but durable impact on recurrent ovarian cancer.

The COVID-19 pandemic greatly affected the delivery of cancer care across the U.S. and globally. In response, oncology societies have established guidance for clinicians on how to best manage ovarian cancer during the COVID-19 era.

Young adults with early-onset cancers appeared at increased risk for harboring specific germline mutations, according to study results presented at the American Association for Cancer Research Virtual Annual Meeting II.